Sertagen

Sertagen is a biotechnology company specializing in the development of long-acting protein therapeutics using its proprietary Serta-Link platform. The company's technology enables site-specific conjugation of polymers or other moieties to proteins, significantly extending their half-life while maintaining biological activity. Sertagen's pipeline includes candidates for growth hormone deficiency and neutropenia, aiming to reduce dosing frequency and improve patient compliance. The company leverages advanced protein engineering to create next-generation biologics with optimized pharmacokinetic profiles. By focusing on site-specific modifications, Sertagen seeks to overcome the limitations of traditional non-specific conjugation methods.